Le Lézard
Classified in: Health
Subjects: NAT, ESG

Flood disaster: Grünenthal donates 400,000 euros as emergency relief


AACHEN, Germany, July 20, 2021 /PRNewswire/ -- Grünenthal is deeply saddened by the situation of the people affected by the flood disaster in Germany. Staff and executive management have set up a relief programme to provide immediate support for people who urgently need help.

Grünenthal donated 200,000 euros as immediate support for the severely affected town of Stolberg. The company will donate an additional 200,000 euros to the coalition "Germany Helps" (Aktion Deutschland Hilft) to support nationwide measures.

"Our thoughts and solidarity are with the people in our neighbourhood in the greater Aachen region and the other affected areas," says Gabriel Baertschi, CEO Grünenthal. "We will provide unbureaucratic support to the helpers on the ground."

Grünenthal supports employees who are personally affected by the flood disaster with financial and material means and paid leave.

About Grünenthal 

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better ? and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of ? 1.3 bn.

More information: www.grunenthal.com

Follow us on: 

LinkedIn: Grunenthal Group 
Instagram: grunenthal

Contact:
Fabia Kehren
Head External Communication & Editorial Management,
Grünenthal
Tel.: +49 241 569-3269
[email protected] 

 

SOURCE Grünenthal Group


These press releases may also interest you

at 21:59
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

at 19:59
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...



News published on and distributed by: